Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 44

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 44
---
 several tumor types that are considered radiosensitive and that are difficult to detect and treat. We intend to develop the...  

  Expand our licensed platform technologies. We have a pipeline of six licensed platform technologies and a joint venture with MD Anderson in Houston, one of the world’s leading cancer research c...  

  Partner with nuclear medicine suppliers. We need to obtain a constant supply of therapeutic isotopes that can be used in our clinical trials. We have partnered with nuclear medicine suppliers t...  

  Being opportunistic in expanding our clinical assets. We have entered into license agreements with prestigious universities and institutions that have allowed us to exclusively use, globally, n...  

  Advance our investigational product candidates towards approval in the United States and elsewhere. We intend to pursue FDA approval of all our product candidates currently in development. All ...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Enter into strategic partnership and collaborations to develop our product candidates. We have entered into strategic partnerships and collaborations with prestigious universities and instituti...  

  Maintain a strong intellectual property portfolio. We have developed a global intellectual property strategy to support our commercial objectives. We are monitoring the results of our research ...  

Clinical Approach

We are pursuing FDA approval
of all our drug candidates currently being developed. We will be working with the FDA to ensure each clinical program is structured to
meet regulatory requirements. FDA approval will be sought following the completion of successful Phase III studies. If we receive FDA
approval for our drug candidates, we will be able to commercialize our drug candidates in the United States and pursue regulatory approval
for the drug to be made available in other jurisdictions, including the European Union, the United Kingdom, China, Japan, Australia and
Canada.

Market Opportunity

The combined annual global
market size of the indications we are targeting is estimated to be over US$6 billion, which is derived from the total addressable market
for the treatment of medical conditions that drug candidates aim to address. Thus, there is significant economic potential to shareholders,
as well as benefit to patients suffering from these medical conditions. Currently we do not have any products approved for commercial
sale. Before receiving any approvals to commercialize our clinical products from the relevant regulators, we will need to conduct clinical
trials according to the rules and regulations of the countries in which we will seek regulatory approvals, including the United States.
As there is no certainty on whether we will obtain any regulatory approval in